PYC Therapeutics advances blinding eye disease drug trials
PYC Therapeutics (ASX:PYC) advances its PYC-001 drug candidate to multiple-dose testing for blinding eye disease ADOA.
PYC Therapeutics (ASX:PYC) advances its PYC-001 drug candidate to multiple-dose testing for blinding eye disease ADOA.
Omnia Metals (ASX:OM1) announced a multi-faceted strategic expansion into the United States' critical minerals sector.
Ovanti (ASX:OVT) raised $5.3 million to scale its global BNPL platform and AI-driven "Super App" strategy.
A Supreme Court justice has ordered Gina Rinehart’s Hancock Prospecting to pay royalties to two rival dynasties.
FDA granted Immutep (ASX:IMM) Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma.
Jim Chalmers defends the Albanese government’s cost-of-living relief as "responsible" despite IMF warnings.
Great Northern Minerals (ASX:GNM) has made the strategic acquisition of the Iron Butte Gold-Silver Project.
Icetana (ASX:ICE) secured a commercial milestone through a new purchase order from SoftBank Robotics Group.
Newmont (ASX:NEM) has suspended all underground operations at its Cadia gold and copper mine following a 4.5 magnitude earthquake.
Orthocell (ASX:OCC) secured approval to supply its Remplir nerve repair device to 221 DoD and Veterans Affairs hospitals.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy
